MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Comorbid conditions associated with Parkinson´s disease: A longitudinal study

D. Santos García, E. Suarez Castro, I. Expósito, T. de Deus, C. Tuñas, D. Núñez Arias, Á. Aneiros, M. López Fernández, J. Naveiro, J. Abella, M.A. Llaneza, V. Vilas, M. Macías (Ferrol, Spain)

Meeting: 2016 International Congress

Abstract Number: 450

Keywords: Development, Levodopa(L-dopa), Parkinsonism, Scales

Session Information

Date: Monday, June 20, 2016

Session Title: Epidemiology

Session Time: 12:30pm-2:00pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: (1)To study what comorbid conditions were present at baseline and 3 years later in a cohort of Spanish PD patients and (2) to analyze the role of comorbidity as predictor of mortality.

Background: Parkinson´s disease (PD) is accompanied by significant comorbidity and that both the extent and type of comorbidity vary as a function of PD duration and age at symptoms onset. Comorbidity should be taken into consideration in the management of the disease.

Methods: One hundred and forty nine non-demented PD patients (57 % males; 70.9 ± 8.6 years old) were included in this 36 months follow-up, longitudinal, monocenter, evaluation study. The International Classification of Diseases, Tenth Revision (ICD-10), Charlson Index (CI), Comorbidity-Polypharmacy Score (CPS) and Elixhauser Comorbidity Measure (ECM) were used to asses comorbidity at baseline and at 3 years.

Results: Seventeen patients died and 8 cases were loss to follow-up. Diseases of the circulatory system (ICD-10/chapter-IX) and endocrine, nutritional and metabolic diseases (ICD-10/chapter-IV) were the most frequent at baseline (53.7% and 51.7%, respectively) and at 3 years (57.3% and 58.1%, respectively). According to ECM, hypertension was the most frequent comorbidity at baseline and at 3 years (41.6% and 46%, respectively). A significant increase in comorbidity was observed at 3 years (n=124): ICD-10 (total number of comorbidities), 5.9 ± 3.8 vs 4.1 ± 1.9 (p<0.001); CI, 0.9 ± 1.4 vs 0.5 ± 0.9 (p<0.001); CPS, 12.4 ± 5.3 vs 9.9 ± 4.1 (p<0.001). Total number and severity of comorbidities at baseline were higher in patients who died (n=141): ICD-10, 5.7 ± 3.3 vs 4.1 ± 1.9 (p=0.006); CI, 1.4 ± 1.6 vs 0.5 ± 0.9 (p=0.001); CPS, 12.7 ± 6.1 vs 9.9 ± 4.1 (p=0.017). Comorbidity was a predictor of death after other covariates adjustment: ICD-10 (total number of comorbidities), hazard ratio 1.261 (95% confidence interval, 1.043-1.524; p=0.017); CI, hazard ratio 1.454 (95% confidence interval, 1.043-2.027; p=0.027).

Conclusions: Comorbidity is frequent in PD patients, increases significantly over time and predicts mortality.

To cite this abstract in AMA style:

D. Santos García, E. Suarez Castro, I. Expósito, T. de Deus, C. Tuñas, D. Núñez Arias, Á. Aneiros, M. López Fernández, J. Naveiro, J. Abella, M.A. Llaneza, V. Vilas, M. Macías. Comorbid conditions associated with Parkinson´s disease: A longitudinal study [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/comorbid-conditions-associated-with-parkinsons-disease-a-longitudinal-study/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/comorbid-conditions-associated-with-parkinsons-disease-a-longitudinal-study/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley